Clinical trials: Diabetic Retinal Disease
Age-related Macular Degeneration, Diabetic Macular Edema
Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections
The specific aims of this study are to compare patient experience with and without a proparacaine drop after povidone iodine.
- Conditions
- Age-related Macular Degeneration, Diabetic Macular Edema, Injection Site, Injection Site Infection
- Trial name
- NCT02951351
- Testing
- Proparacaine, Conjunctival culture
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Proliferative Diabetic Retinopathy, Diabetic Traction Retinal Detachment
Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy
We hypothesized that to reduce the adverse effects of intravitreal bevacizumab on ocular tissue and whole body, intravitreal injection of a low concentration of bevacizumab and conducting vitrectomy shortly after the injection is…
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Traction Retinal Detachment, Vitreous Hemorrhage
- Trial name
- NCT01854593
- Testing
- Bevacizumab, Vitrectomy
- Where
- Japan
- Volunteers
- 69 people
- Sponsor
- Nihon University
Diabetes Mellitus, Diabetic Retinopathy
Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Fundus Images
AEYE-DS is a software device developed to increase compliance with diabetic retinopathy screening by automatically detecting more-than-mild diabetic retinopathy from digital fundus images using Artificial Intelligence (AI)-based…
- Trial name
- NCT04612868
- Testing
- AEYE Software Device
- Where
- United States
- Volunteers
- 531 people
- Sponsor
- AEYE Health Inc
Type 2 Diabetes
DIabetic Retinopathy Candesartan Trials
The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normoalbuminuric type 2 diabetic patients with retinopathy.
- Trial name
- DIRECT (NCT00252694)
- Testing
- candesartan
- Volunteers
- 4,717 people
- Sponsor
- AstraZeneca
Retinal Vein Occlusion, Diabetic Macular Edema
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
The primary objectives of the study are to evaluate the safety and effect of KPI-121 0.25% ophthalmic suspension and KPI-121 1.0% ophthalmic suspension on intraretinal or subretinal fluid secondary to Retinal Vein Occlusion or…
- Trial name
- Molokini (NCT02245516)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Macular Edema
A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.
- Trial name
- NCT00782717
- Testing
- Nepafenac ophthalmic suspension, 0.1% (NEVANAC), Nepafenac ophthalmic suspension vehicle, Prednisolone acetate ophthalmic suspension (OMNIPRED)
- Volunteers
- 263 people
- Sponsor
- Alcon Research
Diabetic Macular Edema
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KESTREL (NCT03481634)
- Testing
- Brolucizumab, Aflibercept
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 566 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema
Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.
To evaluate the change in quality of life (NEI VFQ 25) in subjects with DME during the first year of treatment with aflibercept according to the EU Label.
- Trial name
- AQUA (NCT02581995)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- 76 sites in Austria, Canada and 12 more
- Volunteers
- 560 people
- Sponsor
- Bayer
Diabetic Macular Edema, Retina Vein Occlusion
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety, tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels of GB-102 on subjects with Diabetic Macular Edema…
- Trial name
- NCT04085341
- Testing
- GB-102
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Graybug Vision
DIABETIC MACULAR EDEMA
Triamcinolone vs. Laser for Diabetic Macular Edema
The purpose of this study is to determine if intravitreal triamcinolone acetonide (IVTA) injection at the time of cataract surgery will improve visual acuity and decrease post-operative swelling in diabetic patients requiring…
- Trial name
- IVTA (NCT00229931)
- Testing
- Triamcinolone acetonide, laser
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Oklahoma
Diabetic Macular Edema
Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema
The purpose of this study is to investigate the change in macular edema and the absolute change in visual acuity following intravitreal administered injections of Bevacizumab (Avastin®) or Ranibizumab (Lucentis®) compared with…
- Trial name
- TRIASTIN (NCT00682539)
- Testing
- Bevacizumab (Avastin), Triamcinolone, Lucentis
- Where
- Austria
- Volunteers
- 71 people
- Sponsor
- Medical University of Vienna
Proliferative Diabetic Retinopathy
Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
Diabetic neovascularization refers to a type of diabetic retinopathy which is worsening by the abnormal growth of blood vessels in the back of the eye, damaging the retina.
- Trial name
- NCT00606138
- Testing
- ranibizumab, Laser photocoagulation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rush University Medical Center
Diabetic Macular Edema, Diabetic Retinopathy
ADVM-022 Intravitreal Gene Therapy for DME
A Phase 2, Multi-Center, Randomized, Double-Masked*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema [INFINITY]
- Trial name
- INFINITY (NCT04418427)
- Testing
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- Adverum Biotechnologies, Inc.
Diabetic Retinopathy
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
This study will provide preliminary data on the dose and dose interval related effects of intravitreally administered Avastin on retinal thickness and visual acuity in subjects with Diabetic Macular Edema (DME) to aid in planning…
- Trial name
- Bevacizumab (NCT00336323)
- Testing
- Laser Photocoagulation, Bevacizumab
- Where
- 34 sites in United States
- Volunteers
- 121 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Retinopathy, Macular Edema
Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab
Treatment of diabetic macular edema with intravitreal aflibercept in subjects previously treated with intravitreal anti-Vascular endothelial growth factor (VEGF) agents (ranibizumab or bevacizumab)
- Trial name
- SwapTwo (NCT02559180)
- Testing
- aflibercept
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rishi Singh
Proliferative Diabetic Retinopathy
Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy
To evaluate the effects of oral emixustat hydrochloride (emixustat) on aqueous humor biomarkers associated with proliferative diabetic retinopathy (PDR) from baseline to week 12.
- Trial name
- NCT02753400
- Testing
- emixustat hydrochloride
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Kubota Vision Inc.
Nonproliferative Diabetic Retinopathy
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR).
- Trial name
- PANORAMA (NCT02718326)
- Testing
- Intravitreal aflibercept injection [IAI]
- Where
- 89 sites in United States, Germany and 4 more
- Volunteers
- 402 people
- Sponsor
- Regeneron Pharmaceuticals
Vitreous Hemorrhage
Aflibercept Injection for Proliferative Diabetic Retinopathy
To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.
- Trial name
- NCT01805297
- Testing
- Intravitreal Aflibercept Injection, Standard Vitrectomy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Oklahoma
Nonproliferative Diabetic Retinopathy
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy…
- Trial name
- TIME-2b (NCT03197870)
- Testing
- AKB-9778
- Where
- 53 sites in United States
- Volunteers
- 167 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Age-related Macular Degeneration, Diabetic Macular Edema
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on circulating vascular endothelial growth factor.
- Conditions
- Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02118831
- Testing
- Blood Sample Collection, Aflibercept, Bevacizumab
- Volunteers
- 56 people
- Sponsor
- California Retina Consultants